Why did Replimune’s melanoma therapy Tudriqev get FDA approval now?

Replimune won FDA approval for Tudriqev after two prior rejections, a reversal the source describes as a remarkable turnaround. The excerpt does not explain what specifically changed, but it highlights the approval as a notable regulatory shift that could renew investor interest in a previously damaged melanoma program.